US2003072812A1PendingUtilityA1

Breast cancer eradication program

54
Individually held — no corporate assignee on recordPriority: May 10, 2001Filed: Nov 13, 2002Published: Apr 17, 2003
Est. expiryMay 10, 2021(expired)· nominal 20-yr term from priority
Inventors:David A. Sirbasku
C07K 16/00G01N 33/96A61K 2039/542A61K 2039/505G01N 33/743A61K 31/138G01N 33/5011C07K 16/12C07K 14/70567A61K 35/16G01N 33/6854A61K 2039/585C07K 16/065A61P 35/00C07K 2317/73A61K 39/0008C07K 16/26A61K 33/26G01N 2333/71C07K 2317/52A61K 2039/545G01N 33/575
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating breast cancer that is at least partially ER + is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating breast cancer that is at least partially ER +  comprising administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of at least one iron compound or complex in a suitable carrier.  
     
     
         2 . The method of  claim 1  wherein said iron compound or complex comprises Fe(III) (ferric iron).  
     
     
         3 . The method of  claim 1  wherein said iron compound or complex comprises Fe(II) (ferrous iron).  
     
     
         4 . The method of  claim 1  wherein said administering of said iron compound or complex is followed by performing surgery to remove said tumor.  
     
     
         5 . The method of  claim 1  comprising applying said iron compound or complex to a mastectomy or lumpectomy site.  
     
     
         6 . The method of  claim 1  comprising applying said iron compound or complex to surgical margins of a mastectomy or lumpectomy site.  
     
     
         7 . The method of  claim 1  comprising administering said iron compound or complex to a disseminated/metastatic breast cancer site.  
     
     
         8 . The method of  claim 1  wherein said iron compound or complex comprises a soluble or insoluble composition.  
     
     
         9 . The method of  claim 8  wherein said iron compound or complex comprises a soluble form of Fe(III) chosen from the group consisting of ferric ammonium citrate, ferric ammonium sulfate, ferric chloride, ferric nitrate, ferric sulfate and ferric nitrate hydroxide, and combinations, complexes or polymeric forms thereof.  
     
     
         10 . The method of  claim 8  wherein said iron compound or complex comprises an insoluble form of Fe(III) chosen from the group consisting of ferric deferoxamine activated insoluble matrix.  
     
     
         11 . The method of  claim 10  wherein said activated insoluble matrix is biodegradable.  
     
     
         12 . The method of  claim 11  wherein said activated insoluble matrix is chosen from the group consisting of dextran, starch, insoluble protein and biodegradable synthetic polymers.  
     
     
         13 . The method of  claim 10  wherein said insoluble matrix comprises non-biodegradable implantable beads.  
     
     
         14 . The method of  claim 1  wherein said iron compound or complex comprises INFeD®.  
     
     
         15 . The method of  claim 1  wherein said iron compound or complex comprises radiolabeled  59 Fe(III) or  55 Fe(III).  
     
     
         16 . The method of  claim 1  wherein said iron compound or complex comprises  59 Fe(III) or  55 Fe(III) bound to transferrin.  
     
     
         17 . The method of  claim 1  wherein said iron compound or complex comprises a radioisotope of a metal other than iron that is bound to transferrin or apotransferrin, said radioisotope-bound transferrin or apotransferrin molecule also being bound to at least one Fe(III) atom.  
     
     
         18 . The method of  claim 1  wherein exposure of said tumor site to said iron compound or complex is no more than a few days.  
     
     
         19 . The method of  claim 1  wherein said tumor site is other than a primary localized breast tumor.  
     
     
         20 . A method of treating breast cancer comprising ER −  cancer cells, the method comprising administering to an individual in need thereof a pharmaceutically acceptable composition comprising means for deterring or preventing iron uptake by said ER −  cancer cells.  
     
     
         21 . The method of  claim 20  wherein said means comprises at least one chelator chosen from the group consisting of α-ketohydroxypyridine iron chelators.  
     
     
         22 . The method of  claim 20  wherein said means comprises at least one monoclonal antibody against a transferrin receptor.  
     
     
         23 . The method of  claim 20  comprising administering said composition at a tumor site.  
     
     
         24 . The method of  claim 17  comprising administering said composition in the blood plasma.  
     
     
         25 . The method of  claim 24  wherein said composition comprises means for blocking diferric transferrin from binding to a cellular transferrin receptor.  
     
     
         26 . The method of  claim 20  comprising depleting iron in the diet of said individual.  
     
     
         27 . The method of  claim 20  wherein said composition comprises a blood substitute.  
     
     
         28 . A method of treating breast cancer containing ER +  cells, the method comprising administering to an individual in need thereof a pharmaceutically acceptable composition comprising means for increasing the amount of at least one immunoglobulin inhibitor chosen from the group consisting of IgA, IgM and the Fc domain of IgA or IgM sufficiently to kill at least a portion of said ER +  cells in said individual.  
     
     
         29 . The method of  claim 28  wherein said means comprises oral challenge with an immunogen capable of causing an increase in the number and/or function of IgA or IgM secreting B immunocytes in breast tissue.  
     
     
         30 . A method to aid in deterring the occurrence, growth or progression of breast cancer in a population of susceptible individuals, the method comprising carrying out at least one of the following regimens: 
 (a) in individuals having breast cancer or at risk of developing breast cancer, contacting the breast ductal tissue of said individuals with a cell growth inhibiting amount of an immunoglobulin inhibitor or an immunoglobulin inhibitor mimicking compound;    (b) in individuals with ER +  breast cancer cells, treating a localized tumor or mastectomy or lumpectomy site with an effective amount of a pharmaceutically acceptable form of Fe(II), Fe(III), radioactive Fe(II) or Fe(III), or Fe(III)-bound transferrin or apotransferrin molecules that are also bound to another radioactive metal, sufficient to kill at least a portion of the cancer cells in said tumor or at said mastectomy of lumpectomy site;    (c) in individuals with disseminated ER +  breast cancer cells, administering said Fe(II) or Fe(III) to a metastatic cancer site;    (d) in individuals with localized or disseminated ER +  breast cancer cells, administering locally or systemically a pharmaceutically acceptable composition comprising means for increasing the amount of at least one immunoglobulin inhibitor chosen from the group consisting of IgA, IgM and the Fc domain of IgA or IgM sufficiently to kill at least a portion of said ER +  cells in said individual;    (e) in individuals with ER −  breast cancer cells, administering locally or systemically a pharmaceutically acceptable composition comprising means for deterring or preventing iron uptake by said ER −  cancer cells;    (f) in individuals with localized or disseminated ER −  breast cancer cells, treating said ER −  cancer cells with an effective amount of a pharmaceutically acceptable composition containing radioactive Fe(II) or Fe(III), or Fe(III)-bound transferrin or apotransferrin molecules that are also bound to another radioactive metal, sufficient to kill at least a portion of said ER − cancer cells; and    (g) in individuals with ER −  breast cancer cells, infecting at least a portion of said ER −  cancer cells with a virus vector containing a DNA sequence coding for a poly IgA/IgM binding receptor, and administering locally or systemically an immunoglobulin inhibitor of cancer cell growth or a mimic thereof capable of binding to said receptor.    
     
     
         31 . The method of  claim 30  comprising carrying out at least one of the following regimens: 
 (a) in individuals having breast cancer or at risk of developing breast cancer, enhancing the number of B immunocytes producing IgA or IgM in breast tissue; and  
 (b) immunizing individuals at risk of developing breast cancer against microorganisms known to or suspected of causing breast cancer.

Join the waitlist — get patent alerts

Track US2003072812A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.